

1. NAME OF THE MEDICINAL PRODUCT

Maalox Plus Suspension

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each 5 ml of the suspension contains:

175 mg of aluminium hydroxide, 25 mg of simethicone and 200 mg of magnesium hydroxide.

Also contains 320 mg of sorbitol liquid 70% per 5 ml.

For a full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Oral suspension

White suspension, homogenous after shaking, with the odour and taste of lemon.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Antacid, antiflatulent, relief of sensation of heartburn

4.2 Posology and method of administration

For oral administration. Shake before use.

Adults

5-10 ml, four times a day, taken 20 minutes to 1 hour after meals and at bedtime or as required.

Children

Child 6–12 years: 5 ml 3–4 times daily,
child 12–18 years: 5–10 ml 4 times daily,
taken 20 minutes to 1 hour after meals and at bedtime when required.

Elderly

The normal adult dose is appropriate.

4.3 Contraindications

Should not be used in patients who are hypersensitive to any of the active substances or excipients, are severely debilitated or suffering from kidney failure, or hypophosphataemia.

4.4 Special warnings and precautions for use

Aluminium hydroxide may cause constipation and magnesium salts overdose may cause hypomotility of the bowel; large doses of this product may trigger or aggravate intestinal obstruction and ileus in patients at higher risk such as those with renal impairment, or the elderly.

Aluminium hydroxide is not well absorbed from the gastrointestinal tract, and systemic effects are therefore rare in patients with normal renal function. However, excessive doses or long-term use, or even normal doses in patients with low-phosphorus diets, may lead to phosphate depletion (due to aluminium-phosphate binding) accompanied by increased bone resorption and hypercalciuria with the risk of osteomalacia. Medical advice is recommended in case of long-term use or in patients at risk of phosphate depletion.

In patients with renal impairment, plasma levels of both aluminium and magnesium increase. In these patients, a long-term exposure to high doses of aluminium and magnesium salts may lead to encephalopathy, dementia, microcytic anaemia or worsen dialysis-induced osteomalacia.

Aluminium hydroxide may be unsafe in patients with porphyria undergoing haemodialysis. The prolonged use of antacids in patients with renal failure should be avoided.

This product contains sorbitol (E420). Patients with rare hereditary problems of fructose intolerance should not take this medicine.

Paediatric population

In young children the use of magnesium hydroxide can produce a hypermagnesemia, especially if they present renal impairment or dehydration.

4.5 Interaction with other medicinal products and other forms of interaction

Maalox Plus Suspension should not be taken simultaneously with other medicines as they may interfere with their absorption if taken within 1 hour.

Aluminium-containing antacids may prevent the proper absorption of drugs notably H₂ antagonists, atenolol, bisphosphonates, cefdinir, cefpodoxime, chloroquine, chlorpromazine, ciprofloxacin, cyclines, dasatinib monohydrate, dexamethasone, diflunisal, digoxin, eltrombopag olamine, elvitegravir, ethambutol, fluoroquinolones, glucocorticoids, hydroxychloroquine, indomethacin, iron salts, isoniazid, ketoconazole, levothyroxine, lincosamides, metoprolol, nilotinib, phenothiazine neuroleptics, penicillamine, propranolol, raltegravir potassium, rifampicin, rilpivirine, riociguat, rosuvastatin, sodium fluoride, antiviral treatment combination of tenofovir alafenamide fumarate/emtricitabine/bictegravir sodium, tetracyclines, and vitamins.

With the integrase inhibitors (dolutegravir, raltegravir, bictegravir) the combination should be avoided (please refer to their SmPC for dose recommendations).

As a precaution, stagger the administration times of any orally administered drug and the antacid by at least 2 hours (4 hours for the fluoroquinolones).

Levothyroxine may also bind to simethicone which may delay or reduce the absorption of levothyroxine.

Polystyrene sulphonate:

Caution is advised when used concomitantly with polystyrene sulphonate due to the potential risks of reduced effectiveness of the resin in binding potassium, of metabolic alkalosis in patients with renal failure (reported with aluminium hydroxide and magnesium hydroxide), and of intestinal obstruction (reported with aluminium hydroxide).

Quinidine:

Concomitant use of aluminium products with quinidines may increase the serum levels of quinidine and lead to quinidine overdose.

Tetracycline:

Because of the aluminium content, Maalox Plus Suspension should not be concomitantly administered with tetracycline-containing antibiotics or any tetracycline salts.

Citrates:

Aluminium hydroxide and citrates may result in increased aluminium levels, especially in patients with renal impairment.

Urine alkalinisation secondary to administration of magnesium hydroxide may modify excretion of some drugs; thus, increased excretion of salicylates has been seen.

4.6 Fertility, Pregnancy and lactation

The safety of Maalox Plus Suspension in pregnancy has not been established.

Pregnancy:

There are no available data on Maalox Plus use in pregnant women. No conclusions can be drawn regarding whether or not Maalox Plus is safe for use during pregnancy. Maalox Plus should be used during pregnancy only if the potential benefits to the mother outweigh the potential risks, including those to the foetus.

Lactation:

Because of the limited maternal absorption when used as recommended, minimal amounts, if any, of aluminium hydroxide and magnesium salt combinations are expected to be excreted into breast milk.

Simethicone is not absorbed from the gastrointestinal tract.

No effect on the breastfed newborn/infant are anticipated since the systemic exposure of the breast-feeding woman to aluminium hydroxide, magnesium hydroxide and simethicone is negligible.

4.7 Effects on ability to drive and use machines

None stated

4.8 Undesirable Effects

The following CIOMS frequency rating is used, when applicable:

Very common ($\geq 1/10$), common ($\geq 1/100$ to $<1/10$), uncommon ($\geq 1/1,000$ to $<1/100$), rare ($\geq 1/10,000$ to $<1/1,000$), very rare ($<1/10,000$), not known (cannot be estimated from available data).

Immune system disorders

Frequency not known: Hypersensitivity reactions, such as pruritus, urticaria, angioedema and anaphylactic reactions

Gastrointestinal disorders

Gastrointestinal side-effects are uncommon.

Uncommon: Diarrhoea or constipation (see section 4.4).

Frequency not known: Abdominal pain

Injury, poisoning and procedural complications:

Frequency not known:

Hyperaluminaemia (related to aluminium component).

Metabolism and nutrition disorders

Very rare: Hypermagnesemia, including observations after prolonged administration of magnesium hydroxide to patients with renal impairment

Frequency not known:

Hyperaluminaemia

Hypophosphataemia, in prolonged use or at high doses or even normal doses of the product in patients with low-phosphorus diets which may result in increased bone resorption, hypercalciuria, osteomalacia (see section 4.4).

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form: <https://sideeffects.health.gov.il/>

4.9 Overdose

Serious symptoms are unlikely following overdosage.

Reported symptoms of acute overdose with aluminium hydroxide and magnesium salts combination include diarrhoea, abdominal pain, vomiting.

Large doses of this product may trigger or aggravate intestinal obstruction and ileus in patients at risk (see section 4.4).

Aluminium and magnesium are eliminated through urinary route; treatment of acute overdose consists of administration of IV calcium gluconate, rehydration and forced diuresis. In case of renal function deficiency, haemodialysis or peritoneal dialysis is necessary.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Drugs for acid related disorders; Antacids with antifoaming agents
ATC Code: A02AF02

Dried aluminium hydroxide gel	- antacid
Magnesium hydroxide	- antacid
Simethicone	- antifoaming agent/antiflatulent

Maalox Plus Suspension is a balanced mixture of two antacids and an antiflatulent/antifoaming agent simethicone.

The two antacids are aluminium hydroxide which is a slow acting antacid and magnesium hydroxide which is a fast acting one. The combination produces a fast onset of action and an increase in total buffering time. Aluminium hydroxide on its own is an astringent and may cause constipation. This effect is balanced by the effect of the magnesium hydroxide which is in common with other magnesium salts, may cause diarrhoea.

5.2 Pharmacokinetic properties

None stated

5.3 Preclinical safety data

There are no pre-clinical data of relevance to the prescriber which are additional to that already included in other sections of the SmPC.

6. PHARMACEUTICAL PARTICULARS

6.1 List of Excipients

Sorbitol liquid 70% (non-crystallizing), hydroxypropylcellulose, microcrystalline cellulose and carmellose sodium, lemon flavour, citric acid monohydrate, hydrogen peroxide 30%, Swiss cream flavour, methylcellulose, sodium saccharin, domiphen bromide, purified water.

6.2 Incompatibilities

Not applicable

6.3 Shelf life

The expiry date is indicated on the packaging materials.
Shelf life after first opening: 6 months

6.4 Special precautions for storage

Store below 30°C. Do not freeze.
Shake well before using. Keep bottle tightly closed.

6.5 Nature and contents of container

White polyethylene terephthalate (PET) bottles with polypropylene (PP) cap and polyethylene (PE/LDPE) liner containing 355 ml. Contains also measuring cup.

7. MANUFACTURER

Opella Healthcare International SAS, 82 avenue Raspail, 94250 Gentilly, France

8. MARKETING AUTHORISATION HOLDER AND IMPORTER

Pharmashalom LTD, 21 Ha'Melacha Street, Afek Industrial Zone 4809157 ROSH-HA'AYIN, Israel.

Revised in August 2024.